Hospice patients are expected to die: The treatment focuses on providing comfort to the terminally ill, not finding a cure. To enroll a patient, two doctors certify a life expectancy of six months or less.
But over the past decade, the number of “hospice survivors” in the United States has risen dramatically, in part because hospice companies earn more by recruiting patients who aren’t actually dying, a Washington Post investigation has found. Healthier patients are more profitable because they require fewer visits and stay enrolled longer.
The proportion of patients who were discharged alive from hospice care rose about 50 percent between 2002 and 2012, according to a Washington Post analysis of more than 1 million hospice patients’ records over 11 years in California, a state that makes public detailed descriptions and that, by virtue of its size, offers a portrait of the industry.
The average length of a stay in hospice care also jumped substantially over that time, in California and nationally, according to the analysis. Profit per patient quintupled, to $1,975, California records show.
This vast growth took place as the hospice “movement,” once led by religious and community organizations, was evolving into a $17 billion industry dominated by for-profit companies. Much of that is paid for by the U.S. government — roughly $15 billion of industry revenue came from Medicare last year.
At AseraCare, for example, one of the nation’s largest for-profit chains, hospice patients kept on living. About 78 percent of patients who enrolled at the Mobile, Ala., branch left the hospice’s care alive, according to company figures. As many as 59 percent of patients left the AseraCare branch in nearby Foley, Ala., alive. And at the one in Monroeville, 48 percent were discharged from the hospice alive.
“It was definitely good news,” said Bessie Blount, whose father received hospice care from the Monroeville outfit and left after about a year, she said.
About three years later, her father, Chocolate Blount, 91, is still alive.
The survival rates at AseraCare are emblematic of a problem facing Medicare, which has created a financial incentive for hospice companies to find patients well before death.
Medicare pays a hospice about $150 a day per patient for routine care, regardless of whether the company sends a nurse or any other worker out on that day. That means healthier patients, who generally need less help and live longer, yield more profits.
The trend toward longer stays on hospice care may be costing Medicare billions of dollars a year.
In 2011, nearly 60 percent of Medicare’s hospice expenditure of $13.8 billion went toward patients who stay on hospice care longer than six months, MedPAC, the Medicare watchdog group created by Congress, has reported.
Some of those patients simply outlived a legitimate prognosis of six months.
But much of the data suggests that the trend toward longer stays is a response to the financial incentive.
Consider the difference between the nonprofit and for-profit hospices: While the average nonprofit serves a patients for 69 days, the average for-profit hospice serves a patient for an average of 102 days, according to MedPAC.
Moreover, multiple allegations have arisen from former hospice workers who say that the businesses took in people who weren’t in declining health. Four of the 10 largest hospice companies in the United States, including AseraCare, have been sued by whistleblowers alleging that patients were receiving care they didn’t need. The Justice Department has joined several of these lawsuits, including the one against AseraCare and Vitas, the nation’s largest hospice provider.
Jim Barger, a Birmingham, Ala., lawyer who has filed several of the suits, said the root of the problem is that a company profits when it admits patients who aren’t dying, and it is the hospice itself that helps determine whether a patient is dying. While two doctors certify a patient for hospice care initially, the patient must periodically be reapproved for hospice care. The reapprovals typically are done by hospice physicians.
“Honestly, it makes me ill,” Barger said. Because of the lawsuits, “defense firms make money and my firm has made money. I’d like nothing better at this point than for my job to become obsolete.”
“It must be strange to be told you’re dying, and then not die.”
For five years, Medicare’s watchdog group has been recommending that the payments to hospice companies be revised to eliminate the financial incentive for improper care, but Medicare has not yet done so. To ensure that patients are appropriately selected for hospice care, Medicare relies on strict medical documentation requirements, a spokesman said.
The hospice industry is opposed to fundamental changes to the payment system. Jonathan Keyserling, senior vice president of health policy at the National Hospice and Palliative Care Organization, an industry group, attributes the rise in the number of hospice survivors to changing patient demographics, not fraud. A larger portion of patients today have diseases whose outcomes are harder to predict. That’s because the portion of hospice patients suffering from cancer, a disease that has a more predictable course, has shrunk, he and others in the industry say.
But according to The Washington Post’s analysis, the growth in the average duration of hospice care stems less from the decline in the proportion of cancer patients than from another trend. Patients suffering from a non-cancer ailment began staying longer on hospice: Their average stay in hospice care grew from six weeks to almost 11 weeks on average between 2002 and 2012.
While the lawsuits against the for-profit hospices vary in the details, as a whole they depict an industry in which companies compete for new patients and provide services to patients who are not eligible for them.
Hospice “outreach specialists” and “community education representatives” seek out patients in a variety of ways: They solicit doctors and hospitals who might regularly deal with the terminally ill; they make connections at nursing homes, assisted-living developments and Meals on Wheels groups. They show up at the “health fairs” held at senior centers with, for example, machines that test blood pressure. For families struggling to take care of a loved one, they offer the promise of extra help.
At AseraCare, officials gave advice to their recruiters on how to close a deal with families that are “not ready yet” for hospice, according to a company presentation for Alabama employees. It instructed recruiters to “focus families” by stressing the urgency of a decision, and saying things like “We only have 10 minutes left.”
“Effective communication is the transfer of emotion, not information,” the presentation said.
AseraCare denied the allegations outlined in the lawsuit initiated by whistleblowers at the company.
“Our policies and programs comply with the Congressional intent of the hospice benefit to reduce the stress and anxiety of the end of life of a loved one,” the company said in a statement
Medicare began paying for hospice care in 1983, following a resurgence of interest in end-of-life care. The government benefit, while costly in itself, promised other compensating savings for Medicare: Patients would be choosing home care rather than expensive end-of-life medical treatment.
The treatment of a hospice patient typically focuses on treating pain and symptoms, rather than grasping at a cure. The hospice patient, who is most often living in a private residence or nursing home, receives visits from nurses, aides, social workers and others.
The benefit was quickly embraced by Americans and continues to grow, with Medicare paying for hospice care for more than 1.2 million people annually. In 2000, Medicare spent $2.9 billion on the hospice benefit. By 2012, that figure has risen fivefold, to $15.1 billion.
But as more Americans have taken up hospice care, a profound change has been underway: Big business has moved in.
When Medicare paid its first hospice benefit, the vast majority of hospice-care providers were nonprofit groups. Over the past decade for-profits have come to dominate the industry. Today, nearly 60 percent are for-profit companies, and they may account for an even larger share of patients.
The profits appear to be substantial.
The profit margins as measured by MedPAC, the Medicare watchdog, climbed to 8.7 percent in 2011.
The per-patient operating profit has risen from $353 in 2002 to $1,975 in 2012, according to the analysis of California data.
Medicare has responded with measures that might make it more difficult for hospices to enroll ineligible patients.
In 2009, Medicare added a requirement that the physician, in recommending a patient for hospice care, must include a brief narrative explanation to support a life expectancy of six months or less. In 2010, the agency added a requirement that a physician or nurse practitioner determine a patient’s continued eligibility for hospice in a face-to-face visit.
Next year, the agency will limit the use of vague categories when describing the ailments of hospice patients, specifically prohibiting the use of “debility” and “adult failure to thrive” as primary diagnoses.
And all along, Medicare has capped the average amount of money a company can make on a patient — currently about $25,000 — which amounts to about 180 days of routine care. This is not a per-patient limit, but is averaged over all of a hospice’s patients.
A spokesman for Medicare said the agency is considering hospice payment reform but that no such changes will happen in fiscal 2014.
“While the Medicare hospice benefit provides a choice for beneficiaries to seek the care that best meets their care needs and desires, Medicare has and will continue to take actions to safeguard this benefit from inappropriate use,” said Jonathan Blum, principal deputy administrator of the Centers for Medicare and Medicaid Services, said in a statement.